Syngene International Limited (SYNGENE.BO)

698.25 -0.70 (-0.10%) At close: 03:29PM IST

Syngene International Limited

Velankani Technology Park
Block II, First Floor Electronic City Phase I
Bengaluru 560100
India
91 80 6891 9191
https://www.syngeneintl.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jonathan Brittan Hunt	MD, CEO & Executive Director	84.75M	N/A	1969
Mr. Sibaji Biswas	CFO & Executive Director	34.14M	N/A	N/A
Krishnan G	Head of Investor Relations	N/A	N/A	N/A
Ms. Priyadarshini Mahapatra C.S.	Company Secretary & Compliance Officer	4.72M	N/A	N/A
Mr. Sandeep Nair	Head of Corporate Communications	N/A	N/A	N/A
Mr. Andrew Webster	Chief Human Resources Officer	N/A	N/A	N/A
Dr. Dhananjay Patankar	Head of Pharmaceutical & Biopharmaceutical Development	N/A	N/A	N/A
Mr. Purushottam Shashikant Singnurkar	Head of Formulations Development	N/A	N/A	N/A
Mr. Ajit Manocha	Head of IT	N/A	N/A	N/A
Dr. Jayashree Aiyar Ph.D.	Head of Discovery Biology	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.

Description

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, Japan, Europe, the United States, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, clinical data management, regulatory, biostatistics, and medical writing services. Further, it offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Corporate governance

Syngene International Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.